The Validation Gap
A May 2026 survey by MasterControl found that Eighty-six percent of pharmaceutical leaders say AI is meeting or exceeding their expectations.
In that same survey, 94 percent of pharma quality leaders said they still can’t get their own employees to consistently use the quality systems already in place. Seventy-nine percent said manual, inefficient processes remain a significant pain point on the manufacturing floor, right now.
That’s the real story. Not whether pharma believes in AI, it clearly does. The story is about the distance between that belief and what’s actually running in production.
The standard explanation for this gap is conservatism: pharma is slow, cautious, and resistant to change. That explanation is incomplete, and in its incompleteness, actively harmful. It points toward the wrong fixes. You don’t close a data infrastructure gap with a culture campaign.
The real barriers are specific, not cultural
Data. A 2025 survey by the Pistoia Alliance found that 68 percent of life sciences R&D professionals are already using AI or machine learning in their work. The same survey found 52 percent cite poor data quality as the single biggest barrier to further implementation. Clinical trial results, adverse-event records, and regulatory correspondence sit in siloed systems, legacy formats, and governance frameworks that were never built with AI in mind. The AI project surfaces the debt. The debt slows the project. Concretely, that often means a pharmacovigilance team discovering that ten years of adverse-event narratives were logged in five different formats across three acquired systems and that the AI project can’t start until someone reconciles that, not after.
People. Nearly all pharma quality leaders’ 94 percent cite poor employee engagement with existing systems as a major obstacle, not a minor one. This isn’t a training gap alone. Pharmaceutical teams are among the most credentialed workforces in any industry, and their professional identity is built on personal accountability for decisions that affect patient safety. Asking someone to trust an output they can’t fully audit, in a process where being wrong has real consequences, isn’t a request most people meet with enthusiasm after a vendor demo. Trust here is built through evidence, not persuasion: a system that shows a reviewer exactly which source paragraph an AI-drafted safety narrative came from and lets them check it in seconds rather than take it on faith, earns adoption in a way a slide deck never will. That may be why 70 percent of surveyed pharma tech executives said they planned to invest specifically in AI literacy and training programs in 2025.
Validation. In most industries, deploying a new tool means installing it and iterating when it fails. In a regulated pharmaceutical environment, any tool touching a regulatory document or safety submission must be validated before it goes near production – documentation, testing, and sign-off that can take months. The cost of getting it wrong isn’t a bad quarter. It’s a warning letter, a consent decree, or a submission delay that costs more than the tool would ever have saved. This isn’t a hypothetical burden: the FDA’s first AI-specific draft guidance, issued in January 2025, exists precisely because no risk-based framework for validating these tools existed before it. The EMA’s parallel reflection paper, adopted a few months earlier, makes the same point from the European side. In practice, this means defining a tool’s exact context of use up front- what decision it’s allowed to influence and how much before a single line of output reaches a regulatory document, rather than validating the tool in the abstract and hoping the use case fits later.
What closes the gap
None of these three barriers get solved by waiting for culture to catch up with technology. They get solved directly: fix the data foundation before expecting AI to perform on top of it, build tools around the people who’ll be held accountable for the outcome, rather than around a workflow that quietly routes them out, and validate only once the tool is standing on solid ground.
That sequence- data, then people, then validation is not something this data proves directly; it’s the pattern I’d expect to separate the 86 percent who say AI is meeting expectations from the 14 percent who don’t, and it’s worth testing against your own rollout before assuming it holds.
The barriers don’t resolve on their own. They get solved.